Compare $FTH vs $NVCT | Chartloom

Compare

$FTH vs $NVCT

Faeth Therapeutics, Inc · Nuvectis Pharma Inc

FTH

Faeth Therapeutics, Inc

NVCT

Nuvectis Pharma Inc

Compare $FTH vs $NVCT

Comparing Faeth Therapeutics, Inc and Nuvectis Pharma Inc

FTHFaeth Therapeutics, Inc

NVCTNuvectis Pharma Inc

FTHFaeth Therapeutics, Inc

Market cap

$671M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

79.1%

52W performance

79.1%

FCF yield

-5.0%

NVCTNuvectis Pharma Inc

Market cap

$666M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

148.2%

52W performance

239.0%

FCF yield

-2.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

FTH

NVCT

Detailed metrics comparison

FTH

Faeth Therapeutics, Inc

NVCT

Nuvectis Pharma Inc

Market Cap

FTH$671M

NVCT$666M

Enterprise Value

FTH$644M

NVCT$644M

Price

FTH$26.03

NVCT$21.12

P/E Ratio

FTHN/A

NVCTN/A

P/S Ratio

FTH0.00x

NVCT0.00x

EV/Sales

FTH0.00x

NVCT0.00x

EV/EBITDA

FTH0.00x

NVCT0.00x

P/B Ratio

FTH4.08x

NVCT78.79x

P/FCF Ratio

FTHN/A

NVCTN/A

EV/FCF

FTH-19.02x

NVCT-33.00x

PEG Ratio

FTHN/A

NVCTN/A

Forward P/E (NTM)

FTHN/A

NVCTN/A

Forward P/S (NTM)

FTHN/A

NVCTN/A

Revenue (TTM)

FTH$0

NVCT$0

Revenue Growth (YoY)

FTHN/A

NVCTN/A

Forward Rev Growth

FTH77.6%

NVCT0.0%

Gross Margin (TTM)

FTH0.0%

NVCT0.0%

Operating Margin (TTM)

FTH0.0%

NVCT0.0%

EBITDA Margin (TTM)

FTH0.0%

NVCT0.0%

Net Margin (TTM)

FTH0.0%

NVCT0.0%

FCF Margin (TTM)

FTHN/A

NVCTN/A

Net Income (TTM)

FTH$-196M

NVCT$-30M

FCF (TTM)

FTH$-34M

NVCT$-20M

EPS (TTM)

FTH-$34.65

NVCT-$1.29

ROE (TTM)

FTH-18959.0%

NVCT-16947.0%

ROA (TTM)

FTH-17568.0%

NVCT-9680.0%

ROIC (TTM)

FTH-18946.0%

NVCT-16947.0%

Cash

FTH$27M

NVCT$22M

Debt

FTH$0

NVCT$0

Net Cash/Debt

FTH$27M

NVCT$22M

Current Ratio (TTM)

FTH19.69x

NVCT1.68x

Quick Ratio (TTM)

FTH19.55x

NVCT1.68x

Debt/Equity (TTM)

FTH0.00x

NVCT0.00x

Debt/Assets (TTM)

FTH0.0%

NVCT0.0%

Interest Coverage (TTM)

FTHN/A

NVCTN/A

Net Debt/EBITDA (TTM)

FTH0.00x

NVCT0.00x

Beta

FTH2.05

NVCT-0.23

52W Performance

FTH79.1%

NVCT239.0%

YTD Performance

FTH79.1%

NVCT148.2%

% from 52W High

FTH-38.2%

NVCT-27.9%

% from 52W Low

FTH93.8%

NVCT280.5%

Asset Turnover (TTM)

FTH0.00x

NVCT0.00x

FCF Yield (TTM)

FTH-5.0%

NVCT-2.9%

Earnings Yield (TTM)

FTH-29.1%

NVCT-4.5%

Dividend Yield (TTM)

FTHN/A

NVCTN/A

Rule of 40

FTH0.0

NVCT0.0

EV/GP/RG

FTHN/A

NVCTN/A

Ticker research

View FTH research View NVCT research

Metric	FTH Faeth Therapeutics, Inc	NVCT Nuvectis Pharma Inc
Market & Valuation
Market Cap	$671M	$666M
Enterprise Value	$644M	$644M
Price	$26.03	$21.12
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.08x	78.79x
P/FCF Ratio	N/A	N/A
EV/FCF	-19.02x	-33.00x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	77.6%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-196M	$-30M
FCF (TTM)	$-34M	$-20M
EPS (TTM)	-$34.65	-$1.29
ROE (TTM)	-18959.0%	-16947.0%
ROA (TTM)	-17568.0%	-9680.0%
ROIC (TTM)	-18946.0%	-16947.0%
Financial Health
Cash	$27M	$22M
Debt	$0	$0
Net Cash/Debt	$27M	$22M
Current Ratio (TTM)	19.69x	1.68x
Quick Ratio (TTM)	19.55x	1.68x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.05	-0.23
52W Performance	79.1%	239.0%
YTD Performance	79.1%	148.2%
% from 52W High	-38.2%	-27.9%
% from 52W Low	93.8%	280.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-5.0%	-2.9%
Earnings Yield (TTM)	-29.1%	-4.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View FTH research	View NVCT research

Valuation

P/S Ratio

FTH

0.00x

NVCT

0.00x

EV/FCF

NVCT

-33.00x

FTH

-19.02x

Growth & revenue

Forward Revenue Growth

FTH

77.6%

NVCT

0.0%

Profitability & performance

Gross Margin

FTH

0.0%

NVCT

0.0%

ROE

NVCT

-16947.0%

FTH

-18959.0%

FCF Yield %

NVCT

-2.9%

FTH

-5.0%

52-Week Performance

NVCT

239.0%

FTH

79.1%

Detailed metrics comparison

FTH

Faeth Therapeutics, Inc

NVCT

Nuvectis Pharma Inc

Market Cap

FTH$671M

NVCT$666M

Enterprise Value

FTH$644M

NVCT$644M

Price

FTH$26.03

NVCT$21.12

P/E Ratio

FTHN/A

NVCTN/A

P/S Ratio

FTH0.00x

NVCT0.00x

EV/Sales

FTH0.00x

NVCT0.00x

EV/EBITDA

FTH0.00x

NVCT0.00x

P/B Ratio

FTH4.08x

NVCT78.79x

P/FCF Ratio

FTHN/A

NVCTN/A

EV/FCF

FTH-19.02x

NVCT-33.00x

PEG Ratio

FTHN/A

NVCTN/A

Forward P/E (NTM)

FTHN/A

NVCTN/A

Forward P/S (NTM)

FTHN/A

NVCTN/A

Revenue (TTM)

FTH$0

NVCT$0

Revenue Growth (YoY)

FTHN/A

NVCTN/A

Forward Rev Growth

FTH77.6%

NVCT0.0%

Gross Margin (TTM)

FTH0.0%

NVCT0.0%

Operating Margin (TTM)

FTH0.0%

NVCT0.0%

EBITDA Margin (TTM)

FTH0.0%

NVCT0.0%

Net Margin (TTM)

FTH0.0%

NVCT0.0%

FCF Margin (TTM)

FTHN/A

NVCTN/A

Net Income (TTM)

FTH$-196M

NVCT$-30M

FCF (TTM)

FTH$-34M

NVCT$-20M

EPS (TTM)

FTH-$34.65

NVCT-$1.29

ROE (TTM)

FTH-18959.0%

NVCT-16947.0%

ROA (TTM)

FTH-17568.0%

NVCT-9680.0%

ROIC (TTM)

FTH-18946.0%

NVCT-16947.0%

Cash

FTH$27M

NVCT$22M

Debt

FTH$0

NVCT$0

Net Cash/Debt

FTH$27M

NVCT$22M

Current Ratio (TTM)

FTH19.69x

NVCT1.68x

Quick Ratio (TTM)

FTH19.55x

NVCT1.68x

Debt/Equity (TTM)

FTH0.00x

NVCT0.00x

Debt/Assets (TTM)

FTH0.0%

NVCT0.0%

Interest Coverage (TTM)

FTHN/A

NVCTN/A

Net Debt/EBITDA (TTM)

FTH0.00x

NVCT0.00x

Beta

FTH2.05

NVCT-0.23

52W Performance

FTH79.1%

NVCT239.0%

YTD Performance

FTH79.1%

NVCT148.2%

% from 52W High

FTH-38.2%

NVCT-27.9%

% from 52W Low

FTH93.8%

NVCT280.5%

Asset Turnover (TTM)

FTH0.00x

NVCT0.00x

FCF Yield (TTM)

FTH-5.0%

NVCT-2.9%

Earnings Yield (TTM)

FTH-29.1%

NVCT-4.5%

Dividend Yield (TTM)

FTHN/A

NVCTN/A

Rule of 40

FTH0.0

NVCT0.0

EV/GP/RG

FTHN/A

NVCTN/A

Ticker research

View FTH research View NVCT research

Metric	FTH Faeth Therapeutics, Inc	NVCT Nuvectis Pharma Inc
Market & Valuation
Market Cap	$671M	$666M
Enterprise Value	$644M	$644M
Price	$26.03	$21.12
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	4.08x	78.79x
P/FCF Ratio	N/A	N/A
EV/FCF	-19.02x	-33.00x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	77.6%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-196M	$-30M
FCF (TTM)	$-34M	$-20M
EPS (TTM)	-$34.65	-$1.29
ROE (TTM)	-18959.0%	-16947.0%
ROA (TTM)	-17568.0%	-9680.0%
ROIC (TTM)	-18946.0%	-16947.0%
Financial Health
Cash	$27M	$22M
Debt	$0	$0
Net Cash/Debt	$27M	$22M
Current Ratio (TTM)	19.69x	1.68x
Quick Ratio (TTM)	19.55x	1.68x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.05	-0.23
52W Performance	79.1%	239.0%
YTD Performance	79.1%	148.2%
% from 52W High	-38.2%	-27.9%
% from 52W Low	93.8%	280.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-5.0%	-2.9%
Earnings Yield (TTM)	-29.1%	-4.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View FTH research	View NVCT research